The cost of sepsis;Kosten der sepsis

Anaesthesist

Volumn 55, Issue SUPPL. 2, 2006, Pages

  Moerer, O ^a   Burchardi, H ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cost effectiveness; Cost of care; Innovative drugs; Intensive care; Sepsis

Indexed keywords

DROTRECOGIN;

COST EFFECTIVENESS ANALYSIS; DIAGNOSIS RELATED GROUP; EXPERIMENTAL THERAPY; GERMANY; HEALTH CARE COST; HOSPITAL COST; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LENGTH OF STAY; OUTCOMES RESEARCH; REVIEW; SEPSIS; SOCIOECONOMICS; UNITED STATES;

COST-BENEFIT ANALYSIS; EUROPE; HUMANS; INTENSIVE CARE; LONG-TERM CARE; SEPSIS; UNITED STATES;

EID: 33748947654     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-006-1039-y     Document Type: Review

References (60)

1. Alberti C, Brun-Buisson C, Burchardi H et al. (2002) Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 28: 108-121
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310
3. Angus DC, Linde-Zwirble WT, Clermont G et al. (2003) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 31: 1-11
4. Annane D (2001) Corticosteroids for septic shock. Crit Care Med 29: S117-120
5. Baumgartner JD, Calandra T (1999) Treatment of sepsis: past and future avenues. Drugs 57: 127-132
6. Berghe G van den, Wouters P, Weekers F et al. (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345: 1359-1367
7. Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709
8. Bloos F, Reinhart K (2003) Neue Therapieansätze bei Sepsis. Zentralbl Chir 127: 174-179
9. Boldt J (2004) Können wir uns die Fortschritte der Intensivmedizin noch leisten? Ein Plädoyer für eine offene Debatte. Dtsch Med Wochenschr 129: 36-40
10. Bone RC (1995) Economic analysis of the intensive care unit: a dilemma. Crit Care Med 23: 805
11. Brouwer WB, Koopmanschap MA (1998) How to calculate indirect costs in economic evaluations. Pharmacoeconomics 13: 563-569
12. Burchardi H, Moerer O (2001) Twenty-four hour presence of physicians in the ICU. Crit Care 5: 131-137
13. Carlson RW, Weiland DE, Srivathsan K (1998) Does a full-time, 24-hour intensivist improve care and efficiency? Crit Care Clin 12: 525-551
14. Chalfin DB, Holbein ME, Fein AM, Carlon GC (1993) Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 269: 249-254
15. Chalfin DB, Cohen IL, Lambrinos J (1995) The economics and cost-effectiveness of critical care medicine. Intensive Care Med 21: 952-961
16. Dasta JF, Cooper LM (2002) Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement. Pharmacotherapy 22: 216-222
17. Dellinger RP, Carlet JM, Masur H et al. (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30: 536-555
18. Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM (1999) The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 27: 1760-1767
19. Frampton JE, Foster RH (2004) Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis. Pharmacoeconomics 22: 445-476
20. Friedman G, Silva E, Vincent JL (1998) Has the mortality of septic shock changed with time. Crit Care Med 26: 2078-2086
21. Gyldmark M (1995) A review of cost studies of intensive care units: problems with the cost concept. Crit Care Med 23: 964-972
22. International Sepsis Forum (2001) Guidelines for the management of severe sepsis and septic shock. Intensive Care Med 27 [Suppl 1]: S1-134
23. Jacobs P, Edbrooke D, Hibbert C, Fassbender K, Corcoran M (2001) Descriptive patient data as an explanation for the variation in average daily costs in intensive care. Anaesthesia 56: 643-647
24. Jegers M, Edbrooke DL, Hibbert CL, Chalfin DB, Burchardi H (2002) Definitions and methods of cost assessment: an intensivist's guide. ESICM section on health research and outcome working group on cost effectiveness. Intensive Care Med 28: 680-685
25. Kieft H, Hoepelman AI, Zhou W, Rozenberg-Arska M, Struyvenberg A, Verhoef J (1993) The sepsis syndrome in a Dutch university hospital. Clinical observations. Arch Intern Med 153: 2241-2247
26. Klepzig H, Winten G, Thierolf C, Kiesling G, Usadel KH, Zeiher AM (1998) Behandlungskosten auf einer medizinischen Intensivstation. Dtsch Med Wochenschr 123: 719-725
27. Krishnagopalan S, Dellinger RP (2001) Innovative therapies for sepsis. BioDrugs 15: 645-654
28. Letarte J, Longo CJ, Pelletier J, Nabonne B, Fisher HN (2002) Patient characteristics and costs of severe sepsis and septic shock in Quebec. J Crit Care 17: 39-49
29. Liljas B (1998) How to calculate indirect costs in economic evaluations. Pharmacoeconomics 13: 1-7
30. Lucioni C, Mazzi S, Currado I (2001) Sepsis costs in Italy. Intensive Care Med 27: 284
31. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C (2002) An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347: 993-1000
32. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554
33. Moerer O (2001) Cost assessment in the ICU. J Anaesthesiol Intensivbehandl:175-177
34. Moerer O, Burchardi H (2001) Cost profiles of direct variable costs in ICU patients. Intensive Care Med 27 [Suppl 2]: A286
35. Moerer O, Hein S, Schürgers D, Burchardi H (2000) Cost of infections in the ICU - A matched pairs study. Intensive Care Med 26: A453
36. Moerer O, Schmid A, Hofmann M et al. (2002) Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 28: 1440-1446
37. Moerer O, Schmid A, Plock E, Mgbor U, Schneider H, Burchardi H (2004) Comparison of severity of illness and resource usage in hospitals of different level of care. Intensive Care Med 30: 67
38. Muckart DJ, Bhagwanjee S (1997) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 25: 1789-1795
39. Neilson A, Moerer O, Burchardi H, Schneider H (2004) DRG-based reimbursement of services in German intensive care units: a new concept. Intensive Care Med 30: 1220-1223
40. Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D (2003) Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 18: 217-227
41. Norris C, Jacobs P, Rapoport J, Hamilton S (1995) ICU and non-ICU cost per day. Can J Anaesth 42: 192-196
42. Noseworthy TW, Konopad E, Shustack A, Johnston R, Grace M (1996) Cost accounting of adult intensive care: methods and human and capital inputs. Crit Care Med 24: 1168-1172
43. Oye RK, Bellamy PE (1991) Patterns of resource consumption in medical intensive care. Chest 99: 685-689
44. Quartin AA, Schein RM, Kett DH, Peduzzi PN (1997) Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 277: 1058-1063
45. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP (1995) The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273: 117-123
46. Reinhart K (2004) Echter Fortschritt in der Intensivmedizin muss auch in Zukunft noch finanzierbar sein - Plädoyer für einen öffentlichen Diskurs. Anasthesiol Intensivmed Notfallmed Schmerzther 39: 187-190
47. Rivers E, Nguyen B, Havstad S et al. (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368-1377
48. Sacristan JA, Prieto L, Huete T, Artigas A, Badia X, Chinn C et al. (2004) Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain. Gac Sanit 18: 50-57
49. Salvo I, Cian W de, Musicco M et al. (1995) The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 21 [Suppl 2]: S244-249
50. Sands KE, Bates DW, Lanken PN et al. (1997) Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 278: 234-240
51. Schmid A, Schneider H (2002) The economic burden of sepsis in Austria. Wien Klin Wochenschr 114: 1023-1024
52. Schmid A, Schneider H, Adlof A et al. (2002) Economic burden of illness imposed by severe sepsis in Austria. Wien Klin Wochenschr 114: 697-701
53. Schmid A, Burchardi H, Clouth J, Schneider H (2002) Burden of illness imposed by severe sepsis in Germany. Eur J Health Econom 3: 77-82
54. Schmid A, Pugin J, Chevrolet JC et al. (2004) Burden of illness imposed by severe sepsis in Switzerland. Swiss Med Wkly 134: 97-102
55. Sznajder M, Aegerter P, Launois R, Merliere Y, Guidet B, Cub Rea (2001) A cost-effectiveness analysis of stays in intensive care units. Intensive Care Med 27: 146-153
56. Vanscoy GJ (2002) Management challenge with drotrecogin alfa (activated). Am J Health Syst Pharm 59 [Suppl 1]: S23-29
57. Welton JM, Meyer AA, Mandelkehr L, Fakhry SM, Jarr S (2002) Outcomes of and resource consumption by high-cost patients in the intensive care unit. Am J Crit Care 11: 467-473
58. Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G (2003) Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med 31: 2316-2323
59. Yu DT, Black E, Sands KE et al. (2003) Severe sepsis: variation in resource and therapeutic modality use among academic centers. Crit Care 7: R24-34
60. Zanten AR van, Engelfriet PM, Dillen K van, Veen M van, Nuijten MJ, Polderman KH (2003) Importance of nondrug costs of intravenous antibiotic therapy. Crit Care 7: R184-190